PHA-Exch> Human Rights Guidelines for Pharmaceutical Companies in relation to Access to Medicines: The Sexual and Reproductive Health Context

[Claudio Schuftan]

From: rajat khosla rajat.khosla at gmail.com
Human Rights Guidelines for Pharmaceutical Companies in relation to Access
to Medicines: the Sexual and Reproductive Health Context

Rajat Khosla and Paul Hunt

When Paul Hunt was UN Special Rapporteur (2002-2008), a recurrent theme in
his work was access to medicines. For the most part, he - and colleagues in
the Right to Health Unit - looked at the duties of States in relation to
access to medicines e.g. his report to the UN General Assembly A/61/338,
dated 13 September 2006. However, States reported that when endeavouring to
enhance access to medicines the policies and practices of some
pharmaceutical companies were a very considerable obstacle. Thus, he was
urged to prepare access-to-medicines guidelines for pharmaceutical
companies. After extensive research and wide-ranging consultations over some
years, Paul Hunt and Rajat Khosla wrote 'Human Rights Guidelines for
Pharmaceutical Companies in relation to Access to Medicines'. These
Guidelines were published by the UN General Assembly in A/63/263, dated 11
August 2008. The present publication briefly discusses medicines and sexual
and reproductive health, in particular medicines, HIV/AIDS and the human
papillomavirus (HPV) - HPV being responsible for over 99% of cervical
cancers. In this context, the publication then introduces, and reproduces,
the 'Human Rights Guidelines for Pharmaceutical Companies in relation to
Access to Medicines' that were published by the General Assembly in 2008.

The Publication is available at:

http://www2.essex.ac.uk/human_rights_centre/rth/docs/Final%20pharma%20for%20website.pdf
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://phm.phmovement.org/pipermail/phm-exchange-phmovement.org/attachments/20090227/99f2b38a/attachment-0001.html>